Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

9. Check if this filing amends a previously filed version of this report

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code BUD

16. Specific lobbying issues

H.R. 2847, Commerce, Justice, Science, and Related Agencies Appropriations Act, 2010: trade infringement
H.R. 2892, Department of Homeland Security Appropriations Act, 2010: importation
H.R. 2997, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2010: importation, FDA funding
H.R. 3293, Making appropriations for the Departments of Labor, Health and Human Services, and Education, and related agencies for the fiscal year ending September 30, 2010, and for other purposes: comparative effectiveness, NIH funding, pandemic funding
S. 1298, Department of Homeland Security Appropriations Act, 2010: importation
S. 1406, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2010: importation, FDA funding

17. House(s) of Congress and Federal agencies Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code CPT

16. Specific lobbying issues

H.R. 1260, Patent Reform Act of 2009: reforms of the patent laws
H.R. 1427, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics

H.R. 1548, Pathway for Biosimilars Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics
H.R. 1706, Protecting Consumer Access to Generic Drugs Act of 2009: patent settlements
S. 369, Preserve Access to Affordable Generics Act: patent settlements
S. 515, Patent Reform Act of 2009: reforms of the patent laws
S. 610, Patent Reform Act of 2009: reforms of the patent laws
S. 726, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval pathway for follow-on biologics, including provisions on data exclusivity and patent procedures for biologics
International intellectual property issues

17. House(s) of Congress and Federal agencies Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Commerce - Dept of (DOC), Patent & Trademark Office (PTO), U.S. Trade Representative (USTR),

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code ENV

16. Specific lobbying issues

H.R. 1145, National Water Research and Development Initiative Act of 2009: water quality issues
H.R. 1191, Safe Drug Disposal Act of 2009: drug take back
H.R. 1359, Secure and Responsible Drug Disposal Act of 2009: drug take back
H.R. 3202, Water Protection and Reinvestment Act of 2009: water quality issues
S. 1005, Water Infrastructure Financing Act: water quality issues

17. House(s) of Congress and Federal agencies Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Office of Natl Drug Control Policy (NDCP)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code HCR

16. Specific lobbying issues

H.R. 444, 340B Program Improvement and Integrity Act: 340B program issues (drug pricing program for covered entities)
H.R. 1298, Pharmaceutical Market Access and Drug Safety Act of 2009: importation
H.R. 1427, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval pathway for follow-on biologics
H.R. 1548, Pathway for Biosimilars Act: regulatory approval pathway for follow-on biologics
H.R. 1859, Independent Drug Education and Outreach Act of 2009: academic detailing
H.R. 2502, Comparative Effectiveness Research Act of 2009: comparative effectiveness
H.R. 2824, Doctor-Patient Relationship and Research Protection Act: comparative effectiveness
H.R. 3200, Americas Affordable Health Choices Act: regulatory approval pathway for follow-on biologics, 340B program issues, comparative effectiveness
S. 422, The Heart Disease Education, Analysis Research, and Treatment (HEART) for Women Act: new drug application requirements
S. 488, Access to Cancer Clinical Trials Act of 2009, access to clinical trials
S. 525, Pharmaceutical Market Access and Drug Safety Act of 2009: importation
S. 726, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval pathway for follow-on biologics
S. 767, Independent Drug Education and Outreach Act of 2009: academic detailing
S. 914, Cures Acceleration Network and National Institutes of Health Reauthorization of 2009: basic research and development
S. 1142, Informed Health Care Decision Making Act: drug labeling
S. 1213, Patient-Centered Outcomes Research Act of 2009: comparative effectiveness
S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009: importation
S. 1679, Affordable Health Choices Act: health reform, regulatory approval pathway for follow on biologics, 340B program issues
Americas Healthy Future Act of 2009 Chairmans Mark Senate Finance Committee: comparative effectiveness

17. House(s) of Congress and Federal agencies Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, White House Office, Natl Economic Council (NEC), Health & Human Services - Dept of (HHS), Food & Drug Administration (FDA), Congressional Budget Office (CBO), Agency for Health Care Policy & Research, Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code MMM

16. Specific lobbying issues

H.R. 684, Medicare Prescription Drug Savings and Choice Act: Part D issues
H.R. 3200, Americas Affordable Health Choices Act: Medicaid rebate issues, Part D issues, health reform issues
S. 301, Physician Payments Sunshine Act of 2009: transparency issues
S. 330, Medicare Prescription Drug Savings and Choice Act: Part D issues
S. 1110, Medicare Payment Advisory Commission (MedPAC) Reform Act of 2009: Medicare payment issues
S. 1380, Medicare Payment Advisory Commission Reform Act of 2009: Medicare payment issues
Americas Healthy Future Act of 2009 Chairmans Mark Senate Finance Committee: Medicaid rebate issues, Part D issues, health reform issues
Senate Finance Committee options papers

17. House(s) of Congress and Federal agencies Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, White House Office, Centers For Medicare and Medicaid Services (CMS), Agency for Health Care Policy & Research, Health & Human Services - Dept of (HHS), Congressional Budget Office (CBO), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code TRD

16. Specific lobbying issues

H.R. 3012, Trade Reform, Accountability, Development, and Employment Act of 2009 (TRADE Act of 2009): trade agreements
Korea Free Trade Agreement: intellectual property, market access and public health
International market access and intellectual property issues
Trade enforcement issues

17. House(s) of Congress and Federal agencies Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, U.S. Trade Representative (USTR), Commerce - Dept of (DOC), State - Dept of (DOS)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

Information Update Page - Complete ONLY where registration information has changed.

20. Client new address

21. Client new principal place of business (if different than line 20)

22. New General description of client’s business or activities

LOBBYIST UPDATE

23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client

ISSUE UPDATE

24. General lobbying issue that no longer pertains

AFFILIATED ORGANIZATIONS

25. Add the following affiliated organization(s)

Internet Address: http://www.phrma.org/about_phrma/member_company_list/members/

26. Name of each previously reported organization that is no longer affiliated with the registrant or client

FOREIGN ENTITIES

27. Add the following foreign entities:

28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization